Statistik Asas
| CIK | 1362718 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Tianyin Pharmaceutical Co., Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| May 18, 2016 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES NYSE MKT LLC (the 'Exchange' or 'NYSE MKT') hereby notifies the Securities and Exchange Commission ('SEC') of its intention to remove the entire class of Common Stock (the 'Common Stock') of Tianyin Pharmaceuticals Co. |
|
| May 5, 2016 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act April 29, 2016 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| April 7, 2016 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act April 1, 2016 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| March 2, 2016 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act February 25, 2016 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| January 11, 2016 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS Amendment No. |
|
| January 11, 2016 |
EX-99.1 2 f8k010516a1ex99itianyin.htm PRESS RELEASE DATED JANUARY 11, 2016 Exhibit 99.1 TPI Received Acceptance Letter From NYSE MKT Regarding its Plan of Compliance with Continued Listing Requirements Tianyin Pharmaceutical Inc. (NYSE Amex: TPI) (the “Company”), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded gen |
|
| December 23, 2015 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS Amendment No. |
|
| December 2, 2015 |
TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements Exhibit 99.1 TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements Tianyin Pharmaceutical Inc. (NYSE Amex: TPI) (the ?Company?), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), received notice on November 25, 2015 from the NYSE MKT |
|
| December 2, 2015 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act November 25, 2015 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| November 17, 2015 |
Tianyin Pharmaceutical NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form N-SAR |
|
| October 19, 2015 |
TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements EX-99.1 2 f8k101615ex99itianyinpharma.htm PRESS RELEASE DATED OCTOBER 19, 2015 Exhibit 99.1 TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements Tianyin Pharmaceutical Inc. (NYSE Amex: TPI) (the “Company”), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceut |
|
| October 19, 2015 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act October 16, 2015 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| October 16, 2015 |
CURACRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act September 30, 2015 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| September 28, 2015 |
Tianyin Pharmaceutical NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2015 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form N-SAR For |
|
| September 22, 2015 |
CURACRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act September 22, 2015 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| August 20, 2015 |
Quarterly Report - AMENDMENT NO. 1 TO QUARTERLY REPORT U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Ph |
|
| August 11, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act August 6, 2015 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| August 11, 2015 |
Quarterly Report - QUARTERLY REPORT U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co., Inc. |
|
| July 17, 2015 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act July 13, 2015 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| July 14, 2015 |
Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets 8-K 1 f8k102914tianyinpharma.htm CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act October 29, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. (Exact name of registrant as specifi |
|
| June 25, 2015 |
Submission of Matters to a Vote of Security Holders 8-K 1 f8k062315tianyinpharma.htm CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act June 23, 2015 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. (Exact name of registrant as specified |
|
| June 22, 2015 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8-K 1 f8k062215tianyinpharma.htm CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act June 22, 2015 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. (Exact name of registrant as specified i |
|
| June 22, 2015 |
Tianyin Pharmaceutical Co., Inc. ARTICLE I EX-3.1 2 f8k062215ex3itianyinpharma.htm BY-LAWS Exhibit 3.1 Tianyin Pharmaceutical Co., Inc. BY-LAWS ARTICLE I Stockholders 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place on such date, and at such time as th |
|
| May 26, 2015 |
8-K 1 f8k052115tianyinpharma.htm CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act May 21, 2015 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. (Exact name of registrant as specified in |
|
| May 26, 2015 |
EX-99.1 2 f8k052115ex99itianyin.htm PRESS RELEASE Exhibit 99.1 TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharm |
|
| May 15, 2015 |
Tianyin Pharmaceutical NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 10-Q ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form N-SAR For |
|
| March 31, 2015 |
Tianyin Pharmaceutical DEFINITIVE PROXY STATEMENT U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION INFORMATION REQUIRED IN PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only |
|
| March 13, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co., I |
|
| February 26, 2015 |
TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements Exhibit 99.1 TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements CHENGDU, China, Feb. 26, 2015 /PRNewswire/ - Tianyin Pharmaceutical Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), received notice on February |
|
| February 26, 2015 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act February 24, 2015 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| February 18, 2015 |
TPI / Tianyin Pharmaceutical Co., Inc. NT 10-Q - - NOTIFICATION OF LATE FILING NT 10-Q 1 extf10q1214tianyinpharma.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K ☒ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F |
|
| February 6, 2015 |
TPI to Form Strategic Alliance with Buchang Pharma EX-99.1 2 f8k020615a1ex99itianyin.htm PRESS RELEASE Exhibit 99.1 TPI to Form Strategic Alliance with Buchang Pharma Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today announced that TPI and Buchang Pharmaceutical |
|
| February 6, 2015 |
Other Events, Financial Statements and Exhibits CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS Amendment No. |
|
| January 28, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act January 23, 2015 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| January 16, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 f8k011415tianyinpharma.htm CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act January 14, 2015 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. (Exact name of registrant as specifie |
|
| January 16, 2015 |
TPI to Form Strategic Alliance with Buchang Pharma EX-99.1 2 f8k011415ex99itianyinpharma.htm PRESS RELEASE Exhibit 99.1 TPI to Form Strategic Alliance with Buchang Pharma CHENGDU, China, Jan. 14, 2015 /PRNewswire/ - Tianyin Pharmaceutical Co., Inc. (NYSE MKT: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) tod |
|
| January 6, 2015 |
8-K 1 f8k123114tianyinpharma.htm TIANYIN PHARMACEUTICAL CO, INC. FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act December 31, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. (Exact nam |
|
| December 31, 2014 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co., |
|
| December 9, 2014 |
10-K 1 f10k2014tianyinpharma.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2014 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OF 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: |
|
| November 14, 2014 |
TPI / Tianyin Pharmaceutical Co., Inc. NT 10-Q - - NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K T Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: September 30, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form N-SAR |
|
| October 27, 2014 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS Amendment No. |
|
| October 21, 2014 |
Tianyin Pharmaceutical Received Notices of Non-Compliance from NYSE MKT Exhibit 99.1 Tianyin Pharmaceutical Received Notices of Non-Compliance from NYSE MKT Tianyin Pharmaceutical Inc. (NYSE MKT: TPI, the “Company”), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API), today reported that, on October 15, |
|
| October 21, 2014 |
8-K 1 f8k101514tianyin.htm CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act October 15, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. (Exact name of registrant as specified in i |
|
| October 16, 2014 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act September 30, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| October 15, 2014 |
Tianyin Pharmaceutical Provides Update on Filing of Form 10-K for Fiscal Year Ended June 30, 2014 EX-99.1 2 f8k101514ex99itianyinpharma.htm PRESS RELEASE Exhibit 99.1 Tianyin Pharmaceutical Provides Update on Filing of Form 10-K for Fiscal Year Ended June 30, 2014 CHENGDU, China, Oct. 15, 2014 /PRNewswire/ - Tianyin Pharmaceutical Inc. (NYSE MKT: TPI, the "Company"), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditi |
|
| October 15, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 f8k101514tianyinpharma.htm CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act October 15, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. (Exact name of registrant as specifie |
|
| September 29, 2014 |
TPI / Tianyin Pharmaceutical Co., Inc. NT 10-K - - NOTIFICATION OF LATE FILING NT 10-K 1 extf10k2014tianyinpharma.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2014 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form 20-F ☐ Tr |
|
| July 8, 2014 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS Amendment No. |
|
| June 23, 2014 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS Amendment No. |
|
| May 28, 2014 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act May 28, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| May 19, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 f8k051514tianyinpharma.htm CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act May 15, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. (Exact name of registrant as specified in |
|
| May 19, 2014 |
Exhibit 99.2 Tianyin Pharmaceutical Inc. Third Quarter Fiscal Year 2014 Financial Results Conference Call May 15, 2014 Operator: Ladies and gentlemen, thank you for standing by. Welcome to Tianyin Pharmaceutical Co., Inc. Third Quarter of 2014 Conference Call. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. Instru |
|
| May 19, 2014 |
TPI Reports Third Quarter Fiscal Year 2014 Financial Results Exhibit 99.1 TPI Reports Third Quarter Fiscal Year 2014 Financial Results Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the third quarter fiscal year 2014. Third Quarter Fiscal 2014 |
|
| May 15, 2014 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) 10-Q 1 f10q0314tianyinpharma.htm QUARTERLY REPORT U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi |
|
| May 14, 2014 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS Amendment No. |
|
| May 6, 2014 |
Submission of Matters to a Vote of Security Holders CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20 549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act April 30, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| April 7, 2014 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act April 7, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| March 18, 2014 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION INFORMATION REQUIRED IN PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only |
|
| February 21, 2014 |
Exhibit 99.2 Tianyin Pharmaceutical Inc. Second Quarter Fiscal Year 2014 Financial Results Conference Call February 14, 2014 Operator: Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Tianyin Pharmaceutical Co., Inc., Second Quarter of Fiscal Year 2014 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the presentation, we |
|
| February 21, 2014 |
TPI Reports Second Quarter Fiscal Year 2014 Financial Results EX-99.1 2 f8k021414ex99itianyin.htm PRESS RELEASE DATED FEBRUARY 14, 2014 Exhibit 99.1 TPI Reports Second Quarter Fiscal Year 2014 Financial Results CHENGDU, China, February 14, 2014 - Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical i |
|
| February 21, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 f8k021414tianyin.htm CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act February 14, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. (Exact name of registrant as specified in |
|
| February 14, 2014 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) 10-Q 1 f10q1213tianyinpharma.htm QUARTERLY REPORT U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co |
|
| February 14, 2014 |
Schedule 13G Amendment No. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Tianyin Pharmaceutical Co., Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 88630M104 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Chec |
|
| November 20, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 f8k111513tianyinpharma.htm CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act November 15, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. (Exact name of registrant as specifi |
|
| November 20, 2013 |
TPI Reports First Quarter Fiscal Year 2014 Financial Results EX-99.1 2 f8k111513ex99itianyinpharma.htm PRESS RELEASE Exhibit 99.1 TPI Reports First Quarter Fiscal Year 2014 Financial Results November 15, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial |
|
| November 20, 2013 |
EX-99.2 3 f8k111513ex99iitianyinpharm.htm SCRIPT OF CONFERENCE CALL Exhibit 99.2 Tianyin Pharmaceutical Inc. First Quarter Fiscal Year 2014 Financial Results Conference Call November 15, 2013 Operator. Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Tianyin Pharmaceutical Co., Inc.’s First Quarter of Fiscal Year 2014 Earnings Conference Call. At this time, all par |
|
| November 14, 2013 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co., |
|
| November 4, 2013 |
Changes in Registrant's Certifying Accountant CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act November 4, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| October 15, 2013 |
Tianyin Pharmaceutical Co., Inc. NYSE Amex: TPI 23rd Floor Unionsun Yangkuo Plaza, No 2 Block 3 South Renmin Road, Chengdu 610041, China October 15, 2013 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Jim B. Rosenberg Re: Tianyin Pharmaceutical Co, Inc. Item 4.01 Form 8-K Filed October 8, 2013 File No. 001-34189 Dear Mr. Rosen |
|
| October 15, 2013 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS Amendment No. |
|
| October 15, 2013 |
EX-16.1 2 f8k093013a1ex16itianyin.htm LETTER FROM PATRIZIO AND ZHAO LLC EXHIBIT 16.1 Patrizio & Zhao, LLC Certified Public Accountants and Consultants 322 Route 46 West Member of Parsippany, NJ 07054 Alliance of worldwide accounting firms Tel: (973) 882-8810 Fax: (973) 882-0788 www.pzcpa.com October 10, 2013 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Dear Sir or Mad |
|
| October 8, 2013 |
Changes in Registrant's Certifying Accountant CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act September 30, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| October 2, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 f8k092713tianyinpharma.htm CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act September 27, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. (Exact name of registrant as specif |
|
| October 2, 2013 |
EX-99.2 3 f8k092713ex99iitianyinpharm.htm SCRIPT OF CONFERENCE CALL Exhibit 99.2 Tianyin Pharmaceutical Inc. Fiscal Year 2013 Annual Financial Results Conference Call September 27, 2013 Operator. Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Tianyin Pharmaceuticals’ annual earnings conference call. At this time, all participants are in a listen-only mode. Follow |
|
| October 2, 2013 |
TPI Announces Fiscal Year 2013 Financial Results Exhibit 99.1 TPI Announces Fiscal Year 2013 Financial Results September 27, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2013. Fiscal Year 2013 Ended June 30, 2 |
|
| September 26, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OF 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: TIANYIN PHARMACEUTICAL CO., INC. (Exact name o |
|
| July 1, 2013 |
- POST EFFECTIVE AMENDMENT NO.4 TO As filed with the Securities and Exchange Commission on July 1, 2013 Registration No. |
|
| May 20, 2013 |
EX-99.2 3 f8k051513ex99iitianyin.htm SCRIPT OF CONFERENCE CALL ON MAY 15, 2013 Exhibit 99.2 Tianyin Pharmaceutical Co., Inc. (TPI) F3Q13 Earnings Call May 15, 2013 9:00 AM EST Operator. Good day ladies and gentlemen. Thank you for standing by. Welcome to the Tianyin Pharmaceuticals Incorporated’s Fiscal Year 2013 Third Quarter Earnings conference call. During today’s presentation, all parties will |
|
| May 20, 2013 |
Exhibit 99.1 TPI Reports Third Quarter Fiscal Year 2013 Financial Results CHENGDU, China, May 14, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for third quarter of the fiscal year |
|
| May 20, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 f8k051513tianyin.htm CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act May 15, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. (Exact name of registrant as specified in its c |
|
| May 15, 2013 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co., Inc. |
|
| May 13, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act May 8, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| May 13, 2013 |
Exhibit 99.1 Tianyin Pharmaceutical Management Hosts Annual General Meeting May 8, 2013 10:00 AM ET Operator.Good morning, ladies and gentlemen. Now we are starting the Annual Meeting of Tianyin Pharmaceutical Co., Inc. (“TPI”) for the fiscal year ended June 30, 2012. We have Dr. James Tong and the Company’s legal counsel, Mr. Louis Taubman on the floor, as well as some shareholders. James Jiayuan |
|
| May 9, 2013 |
Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders 8-K 1 f8k050813tianyin.htm CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act May 8, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. (Exact name of registrant as specified in its c |
|
| March 18, 2013 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION INFORMATION REQUIRED IN PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only |
|
| March 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OF 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: TIANYIN PHARMACEUTICAL CO. |
|
| March 15, 2013 |
Tianyin Pharmaceutical Co., Inc. NYSE Amex: TPI 23rd Floor UnionsunYangkuo Plaza, No 2 Block 3 South Renmin Road, Chengdu 610041, China March 15, 2013 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Mr. Jim B. Rosenberg Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2012 Filed September 28, 20 |
|
| February 19, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act February 14, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| February 19, 2013 |
Exhibit 99.2 Tianyin Pharmaceutical Co., Inc. (“TPI”) Second Quarter of Fiscal Year 2013 Earnings Call February 14, 2013 Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Tianyin Pharmaceutical, Inc.’s (“TPI”) Second Quarter of Fiscal Year 2013 Earnings Conference Call. (Operator instructions.) And as a reminder this call is being recorded today, February 1 |
|
| February 19, 2013 |
TPI Reports Second Quarter Fiscal Year 2013 Financial Results Exhibit 99.1 TPI Reports Second Quarter Fiscal Year 2013 Financial Results CHENGDU, China, February 14, 2013 - Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for second quarter of the fis |
|
| February 14, 2013 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co., I |
|
| December 7, 2012 |
- POST EFFECTIVE AMENDMENT NO.3 TO As filed with the Securities and Exchange Commission on December 7, 2012 Registration No. |
|
| November 23, 2012 |
Exhibit 99.1 TPI Reports First Quarter Fiscal Year 2013 Financial Results CHENGDU, China, Nov. 15, 2012 - Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for first quarter of the fiscal ye |
|
| November 23, 2012 |
Exhibit 99.2 Tianyin Pharmaceutical Co., Inc. (“TPI”) First Quarter of Fiscal Year 2013 Earnings Call November 15, 2012 8:30 AM ET Operator Good morning ladies and gentlemen, and welcome to the Tianyin Pharmaceutical Company’s First Quarter of Fiscal Year 2013 (“F1Q 2013”) Earnings Results Conference Call. (Operator instructions.) I would now like to turn the conference over to James Tong, Chief F |
|
| November 23, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act November 15, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| November 14, 2012 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co., |
|
| November 2, 2012 |
Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 November 2, 2012 U.S. Securities and Exchange Commission Division of Corporate Finance Washington, D.C. 20549 Attn: Jeffrey Riedler Re: Tianyin Pharmaceutical Co., Inc. Post-Effective Amendment No. 1 Registration Statement on Form S-1 Filed March 27, 2012 Post-Effectiv |
|
| October 23, 2012 |
October 23, 2012 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Nandini Acharya Re: Tianyin Pharmaceutical Co., Inc. Post Effective Amendment No. 1 to Form S-1 Post Effective Amendment No. 2 to Form S-1 File No. 333-163563 Dear Ms. Acharya: This letter is provided in response to your letters dated April 5, 2012 and June 27, 20 |
|
| October 23, 2012 |
- POST EFFECTIVE AMENDMENT NO.3 TO As filed with the Securities and Exchange Commission on October 23, 2012 Registration No. |
|
| October 3, 2012 |
Exhibit 99.2 Tianyin Pharmaceutical Co., Inc. Fiscal 2012 Earnings Call September 28, 2012 Operator: Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Tianyin Pharmaceutical Inc.'s Fiscal Year 2012 Earnings Conference Call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be opened for questions. If |
|
| October 3, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act September 28, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| October 3, 2012 |
Exhibit 99.1 TPI Reports Fiscal Year 2012 Financial Results CHENGDU, China, September 28, 2012 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2012. Fiscal Year 2012 En |
|
| September 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OF 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: TIANYIN PHARMACEUTICAL CO., INC. (Exact name o |
|
| June 13, 2012 |
As filed with the Securities and Exchange Commission on June 13, 2012 Registration No. |
|
| June 6, 2012 |
INDEPENDENT DIRECTOR AGREEMENT TIANYIN PHARMACEUTICAL CO., INC. Exhibit 10.2 INDEPENDENT DIRECTOR AGREEMENT OF TIANYIN PHARMACEUTICAL CO., INC. This INDEPENDENT DIRECTOR AGREEMENT (the “Agreement”) is made and entered into as of this 4th day of June, 2012 (the “Effective Date”), by and between Tianyin Pharmaceutical Co., Inc., a Delaware corporation (the “Company”), and Mr. Bo Tan, a citizen of China, with a permanent residence at (the “Independent Director”). |
|
| June 6, 2012 |
Exhibit 10.1 Consulting Agreement This agreement (the “Agreement”) dated and effective this 4th day of June, 2012 by and between Tianyin Pharmaceutical Co., Inc, a Delaware corporation (“TPI” or the “Company”), and James T. McCubbin (“Consultant”). Recitals I. TPI desires to obtain consulting and advisory services from Consultant. II. Consultant, on a part time basis, is in the business of providi |
|
| June 6, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act June 4, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| May 17, 2012 |
Exhibit 99.1 TPI Reports Third Quarter Fiscal Year 2012 Financial Results CHENGDU, China, May 15, 2012 - Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the third quarter of fiscal yea |
|
| May 17, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act May 17, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| May 17, 2012 |
Exhibit 99.2 Tianyin Pharmaceutical Co., Inc. (TPI) F3Q12 Earnings Call May 15, 2012 9:00 AM ET Operator Good day ladies and gentlemen thank you for standing by. Welcome to the Tianyin Pharmaceutical Incorporated Third quarter fiscal 2012 annual financial results conference call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference will |
|
| May 15, 2012 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co., Inc. |
|
| April 13, 2012 |
Submission of Matters to a Vote of Security Holders 8-K 1 f8k041112tianyin.htm CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act April 11, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co., Inc. (Exact name of registrant as specified in it |
|
| March 27, 2012 |
As filed with the Securities and Exchange Commission on March 27, 2012 Registration No. |
|
| March 2, 2012 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION INFORMATION REQUIRED IN PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only |
|
| February 24, 2012 |
Under the Securities Exchange Act of 1934 (Amendment No. 5) TIANYIN PHARMACEUTICAL CO., INC. (Name of Issuer) SCHEDULE 13D/A Common Stock, $.001 par value (Title of Class of Securities) 88630M104 (CUSIP Number) Unit 06, 21/F, Beautiful Group Tower, 77 Connaught Road, Central, Hong Kong Telephone: (852) 3583 3340; Fax: (852) 3585 6021 (Name, Address and Telephone Number of Person Authorized to Rece |
|
| February 17, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act February 14, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| February 17, 2012 |
Exhibit 99.2 Tianyin Pharmaceutical Inc. (TPI) F2Q12 Earnings Call February 14, 2012 8:30 AM ET Operator Good day ladies and gentlemen thank you for standing by. Welcome to the Tianyin Pharmaceutical Co., Inc., second quarter 2012 annual financial results conference call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be open |
|
| February 17, 2012 |
Exhibit 99.1 TPI Reports Second Quarter Fiscal Year 2012 Financial Results CHENGDU, China, Feb. 14, 2012 - Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the second quarter of Fiscal |
|
| February 14, 2012 |
SC 13G/A 1 secfiling.htm DISCLOSURE DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tianyin Pharmaceutical Co., Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 88630M104 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Tianyin Pharmaceutical Co., Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 88630M104 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 13, 2012 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2011 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co., I |
|
| December 1, 2011 |
Under the Securities Exchange Act of 1934 (Amendment No. 4) TIANYIN PHARMACEUTICAL CO., INC. (Name of Issuer) SCHEDULE 13D/A Common Stock, $.001 par value (Title of Class of Securities) 88630M104 (CUSIP Number) Unit 06, 21/F, Beautiful Group Tower, 77 Connaught Road, Central, Hong Kong Telephone: (852) 3583 3340; Fax: (852) 3585 6021 (Name, Address and Telephone Number of Person Authorized to Rece |
|
| November 30, 2011 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act November 25, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| November 23, 2011 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act November 18, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| November 18, 2011 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No.1 (Mark One) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No.1 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pha |
|
| November 17, 2011 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act November 14, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| November 17, 2011 |
Exhibit 99.1 TPI Reports First Quarter Fiscal Year 2012 Financial Results CHENGDU, China, Nov. 14, 2011 Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the first quarter of Fiscal Year 2012. Fi |
|
| November 17, 2011 |
Exhibit 99.2 Tianyin Pharmaceutical, Incorporated First Quarter 2012 Annual Financial Results Conference Call November 14, 2011 Operator: Good day, ladies and gentleman. Thank you for standing by. And welcome to the Tianyin Pharmaceutical Inc. First Quarter 2012 Annual Financial Results Conference Call. During today?s presentation, all parties will be in a listen-only mode. Following our presentat |
|
| November 14, 2011 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co., |
|
| November 10, 2011 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act November 10, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| October 4, 2011 |
Exhibit 99.2 Tianyin Pharmaceutical Inc. Fiscal Year 2011 Annual Financial Results Conference Call September 27, 2011 Operator: Good day, ladies and gentleman. Thank you for standing by. Welcome to the Tianyin Pharmaceutical Fiscal Year 2011 Annual Financial Results Conference Call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference w |
|
| October 4, 2011 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act September 27, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| October 4, 2011 |
TPI Announces Fiscal Year 2011 Financial Results Exhibit 99.1 TPI Announces Fiscal Year 2011 Financial Results September 27, 2011 Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the Fiscal Year 2011. Fiscal year 2011 ending June 30, 2011 financial high |
|
| September 28, 2011 |
10-K 1 tpi10k63011r.htm TIANYIN PHARMACEUTICAL CO., INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K |X| ANNUAL REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2011 || TRANSITION REPORT PURSUANT TO SECTION 13 OF 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION |
|
| August 22, 2011 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2010 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tiany |
|
| August 22, 2011 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin |
|
| August 22, 2011 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No.1) (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tiany |
|
| August 22, 2011 |
Tianyin Pharmaceutical Co., Inc. NYSE Amex: TPI 23rd Floor Unionsun Yangkuo Plaza, No 2 Block 3 South Renmin Road, Chengdu 610041, China August 22, 2011 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Mr. Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2010 File No. 001-34189 Dear M |
|
| July 7, 2011 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act June 10, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| July 7, 2011 |
Tianyin Pharmaceutical Co., Inc. NYSE Amex: TPI 23rd Floor Unionsun Yangkuo Plaza, No 2 Block 3 South Renmin Road, Chengdu 610041, China July 7, 2011 U.S. Securities and Exchange Commission Accounting Branch 100 F. Street, N.E. Washington, D.C. 20549 Attn: Joel Parker Re: Tianyin Pharmaceutical Co., Inc. Item 4.02, Form 8-K filed June 16, 2011 File No. 001-34189 Dear Mr. Parker: This letter is pro |
|
| July 7, 2011 |
Tianyin Pharmaceutical Co., Inc. NYSE Amex: TPI 23rd Floor Unionsun Yangkuo Plaza, No 2 Block 3 South Renmin Road, Chengdu 610041, China July 7, 2011 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Mr. Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2010 File No. 001-34189 Dear Mr. |
|
| June 16, 2011 |
TPI Board Reinstates Stock Repurchase Program EXHIBIT 99.1 TPI Board Reinstates Stock Repurchase Program Friday June 3, 2011, 8:02 am EDT Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced that the Board of Directors has reinstated the stock repurchase program tha |
|
| June 16, 2011 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act June 10, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| May 20, 2011 |
Exhibit 99.2 Tianyin Pharmaceutical, Inc. Third Quarter Fiscal Year 2011 Earnings Results May 17, 2011 Operator: Good morning, ladies and gentleman, and thank you for standing by. And welcome to the Tianyin Pharmaceutical Incorporated Third Quarter 2011 Earnings Conference Call. At this time, all participants are in a listen-only mode, and following the presentation, instructions will be given for |
|
| May 20, 2011 |
Regulation FD Disclosure, Financial Statements and Exhibits CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act May 16, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| May 20, 2011 |
EX-99.1 2 ex99one.htm PRESS RELEASE DATED MAY 16, 2011 Exhibit 99.1 TPI Reports Record Third Quarter Fiscal Year 2011 Financial Results May 16, 2011 CHENGDU, China, May 16, 2011 /PRNewswire-Asia-FirstCall/ - Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and ot |
|
| May 16, 2011 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co., |
|
| May 12, 2011 |
Tianyin Pharmaceutical Co., Inc. NYSE Amex: TPI 23rd Floor Unionsun Yangkuo Plaza, No 2 Block 3 South Renmin Road, Chengdu 610041, China May 12, 2011 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period E |
|
| May 9, 2011 |
HUNTER TAUBMAN WEISS LLP New York ■ Washington, DC ■ Miami HUNTER TAUBMAN WEISS LLP New York ■ Washington, DC ■ Miami Louis Taubman (Admitted NY) Email: LTaubman@htwlaw. |
|
| May 3, 2011 |
HUNTER TAUBMAN WEISS LLP New York ■ Washington, DC ■ Miami HUNTER TAUBMAN WEISS LLP New York ■ Washington, DC ■ Miami Louis Taubman (Admitted NY) Email: LTaubman@htwlaw. |
|
| April 25, 2011 |
HUNTER TAUBMAN WEISS LLP New York ■ Washington, DC ■ Miami HUNTER TAUBMAN WEISS LLP New York ■ Washington, DC ■ Miami Louis Taubman (Admitted NY) Email: LTaubman@htwlaw. |
|
| April 4, 2011 |
April 4, 2011 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period Ended December 31, 2009 File No. 001-34189 Dear Mr. Wyman: This letter is provided in response to your letter dated February 17, 2011, re |
|
| March 21, 2011 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act March 21, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| March 18, 2011 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act March 17, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| March 18, 2011 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act March 14, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| March 18, 2011 |
TPI 2010 Shareholder Annual Meeting on 3/21/11 to Be Held at 100 Wall Street, near NYSE Exhibit 99.1 TPI 2010 Shareholder Annual Meeting on 3/21/11 to Be Held at 100 Wall Street, near NYSE CHENGDU, China, March 17, 2011 /PRNewswire-Asia-FirstCall/ - Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals announced the relocation of TP |
|
| March 3, 2011 |
March 3, 2011 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period Ended December 31, 2009 File No. 001-34189 Dear Mr. Wyman: This letter is provided in response to your letter dated February 17, 2011, re |
|
| February 28, 2011 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION INFORMATION REQUIRED IN PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission |
|
| February 22, 2011 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act February 15, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| February 22, 2011 |
Exhibit 99.1 TPI Reports Record Second Quarter Fiscal Year 2011 Financial Results February 14, 2011 CHENGDU, China, Feb. 14, 2011 /PRNewswire-Asia-FirstCall/ - Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial res |
|
| February 22, 2011 |
Exhibit 99.2 Tianyin Pharmaceutical, Inc. Second Quarter Fiscal Year 2011 Earnings Results February 15, 2011 Operator: Good morning, ladies and gentleman, and thank you for standing by. Welcome to the Tianyin Pharmaceutical Inc. Second Quarter Earnings Conference Call. At this time, all participants are in listen-only mode, and following the presentation, instructions will be given for the questio |
|
| February 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tianyin Pharmaceutical Co., Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 88630M104 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Tianyin Pharmaceutical Co., Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 88630M104 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 14, 2011 |
Schedule 13G Amendment No. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Tianyin Pharmaceutical Co., Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 88630M104 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 11, 2011 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2010 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co |
|
| January 18, 2011 |
January 18, 2011 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period Ended December 31, 2009 File No. 001-34189 Dear Mr. Wyman: This letter is provided in response to your letter dated December 1, 2010, |
|
| January 14, 2011 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act January 14, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| January 14, 2011 |
Exhibit 99.1 WARRANT AMENDMENT This WARRANT AMENDMENT (this “Amendment”) is dated as of January 14, 2010 by and among Tianyin Pharmaceutical Co., Inc., a Delaware corporation (the “Company”), and the investors signatory hereto (each an “Investor”, collectively, the “Investors”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Securities |
|
| December 13, 2010 |
December 13, 2010 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Mr. Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 File No. 001-34189 Dear Mr. Wyman: I am counsel to Tianyin Pharmaceutical Co., Inc. (“Tianyin”). Tianyin received your comment letter December 1, 2010 regarding the a |
|
| December 2, 2010 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act November 30, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| December 2, 2010 |
Exhibit 99.1 FORM OF WARRANT AMENDMENT This WARRANT AMENDMENT (this ?Amendment?) is dated as of November 30,2010 by and among Tianyin Pharmaceutical Co., Inc., a Delaware corporation (the ?Company?), and the investors signatory hereto (each an ?Investor?, collectively, the ?Investors?). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Se |
|
| November 23, 2010 |
November 23, 2010 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period Ended December 31, 2009 File No. 001-34189 Dear Mr. Wyman: This letter is provided in response to your letter dated October 29, 2010, |
|
| November 16, 2010 |
Address: 23rd Floor Unionsun Yangkuo Plaza No. 2, Block 3, South Renmin Road Chengdu, 610041 China Exhibit 99.1 Tianyin Reports Record First Quarter Fiscal Year 2011 Financial Results Press Release Source: Tianyin Pharmaceutical Co., Inc. On Wednesday November 10, 2010, 14:42:52 GMT Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals ann |
|
| November 16, 2010 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act November 11, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| November 16, 2010 |
Exhibit 99.2 Tianyin Pharmaceutical, Inc. First Quarter Fiscal Year 2011 Earnings Results November 11, 2010 Operator: Ladies and gentlemen, thank you for standing by and welcome to the Tianyin Pharmaceutical, Inc. Fiscal Year 2010 Earnings conference call. During today’s presentation all parties will be in a listen-only mode. Following the presentation the conference will be open for questions. If |
|
| November 12, 2010 |
Under the Securities Exchange Act of 1934 (Amendment No. 3) TIANYIN PHARMACEUTICAL CO., INC. (Name of Issuer) SCHEDULE 13D/A Common Stock, $.001 par value (Title of Class of Securities) 88630M104 (CUSIP Number) Time Poly Management Ltd. Unit 06, 21/F, Beautiful Group Tower, 77 Connaught Road, Central, Hong Kong Telephone: (852) 3583 3340; Fax: (852) 3585 6021 (Name, Address and Telephone Number of |
|
| November 12, 2010 |
FORM OF RULE 10B5-1 TRADING PLAN EXHIBIT 7.1 FORM OF RULE 10B5-1 TRADING PLAN This Trading Plan (the ?Trading Plan?) is entered into on October 11, 2010 (?Seller?s Adoption Date?) between Time Poly Management Limited (?Seller?) and UBS Financial Services Inc. (?UBSFS?) for the purpose of selling shares of common stock (?Stock?) of Tianyin Pharmaceutical Co., Inc. (?Issuer?), TPI (Ticker), including; Stock that the Seller has the |
|
| November 12, 2010 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical C |
|
| November 5, 2010 |
Louis Taubman (Admitted NY) Email [email protected] November 5, 2010 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Mr. Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 File No. 001-34189 Dear Mr. Wyman: I am counsel to Tianyin Pharmaceutical Co., Inc. (“Tianyin”). Tianyin received you |
|
| October 5, 2010 |
Exhibit 99.2 Tianyin Pharmaceutical Inc. Fiscal Year 2010 Earnings Conference Call September 30, 2010 Operator: Ladies and gentlemen, thank you for standing by and welcome to the Tianyin Pharmaceutical Inc. Fiscal Year 2010 Earnings conference call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be opened for questions. If yo |
|
| October 5, 2010 |
Regulation FD Disclosure, Financial Statements and Exhibits CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act September 29, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| October 5, 2010 |
EX-99.1 2 ex99one.htm PRESS RELEASE DATED SEPTEMBER 29, 2010 Exhibit 99.1 Tianyin Reports Record Fiscal 2010 Financial Results Press Release Source: Tianyin Pharmaceutical Co., Inc. On Wednesday September 29, 2010, 8:46 am EDT CHENGDU, China, Sept. 29 /PRNewswire-Asia-FirstCall/ - Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a biopharmaceutical company that specializes in patented biopharma |
|
| September 29, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K |X| ANNUAL REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2010 || TRANSITION REPORT PURSUANT TO SECTION 13 OF 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: TIANYIN PHARMACEUTICAL CO., INC. (formerly |
|
| September 28, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission file number: 001-28911 NOTIFICATION OF LATE FILING (Check One): [X ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2010 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] |
|
| September 22, 2010 |
Tianyin Pharmaceutical Co., Inc. NYSE Amex: TPI 23rd Floor Unionsun Yangkuo Plaza, No 2 Block 3 South Renmin Road, Chengdu 610041, China September 22, 2010 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Filed September 24, 2009 F |
|
| September 17, 2010 |
Louis Taubman (Admitted NY) Email [email protected] September 17, 2010 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Mr. Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 File No. 001-34189 Dear Mr. Wyman: I am counsel to Tianyin Pharmaceutical Co., Inc. (“Tianyin”). Tianyin received y |
|
| June 30, 2010 |
June 30, 2010 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Filed September 24, 2009 File No. 001-34189 Dear Mr. Wyman: This letter is provided in response to your letter dated May 28, 2010, regarding the above-referenced Form 1 |
|
| June 8, 2010 |
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
Regulation FD Disclosure, Financial Statements and Exhibits CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act June 3, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 8, 2010 |
[NEXT SLIDE] [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] [HOME] |
|
| June 4, 2010 |
Louis Taubman (Admitted NY) Email [email protected] June 4, 2010 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Mr. Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 File No. 001-34189 Dear Mr. Wyman: I am counsel to Tianyin Pharmaceutical Co., Inc. (“Tianyin”). Tianyin received your co |
|
| May 18, 2010 |
Exhibit 99.1 Tianyin Pharmaceutical Co., Inc. F3Q10 (Qtr End 03/31/10) Earnings Call Transcript F3Q10 (Qtr End 03/31/10) Earnings Call May 12, 2010 09:00 am ET Executives Dr. Jiang Guoqing - Chairman and Chief Executive Officer Dr. James Jiayuan Tong ? Chief Financial Officer, Chief Business & Development Officer, Director Analysts Angel Liu ? Pope asset Jamie Clement - Sidoti Boyd Hinds - Equinox |
|
| May 18, 2010 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act May 12, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| May 18, 2010 |
Tianyin Reports Record Third Quarter 2010 Financial Results Exhibit 99.2 Tianyin Reports Record Third Quarter 2010 Financial Results Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a biopharmaceutical company that specializes in the modernized traditional Chinese medicine ("TCM") and branded generics today announced fiscal results for its third quarter ended March 31, 2010. Third quarter fiscal year 2010 ending March 31, 2010 financial highlights - Q3 |
|
| May 11, 2010 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co., |
|
| April 15, 2010 |
SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) TIANYIN PHARMACEUTICAL CO., INC. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 88630M104 (CUSIP Number) Stewart Shiang Lor Unit 06, 21/F, Beautiful Group Tower, 77 Connaught Road, Central, Hong Kong Telephone: (852) 3583 3340; Fax: (852) 3585 6021 (Name, Address and Telephone Number of Person Au |
|
| April 14, 2010 |
Under the Securities Exchange Act of 1934 (Amendment No. 2) TIANYIN PHARMACEUTICAL CO., INC. (Name of Issuer) SCHEDULE 13D/A Common Stock, $.001 par value (Title of Class of Securities) 88630M104 (CUSIP Number) Time Poly Management Ltd. Unit 06, 21/F, Beautiful Group Tower, 77 Connaught Road, Central, Hong Kong Telephone: (852) 3583 3340; Fax: (852) 3585 6021 (Name, Address and Telephone Number of |
|
| April 2, 2010 |
Under the Securities Exchange Act of 1934 (Amendment No.1) TIANYIN PHARMACEUTICAL CO., INC. (Name of Issuer) SCHEDULE 13D/A Common Stock, $.001 par value (Title of Class of Securities) 88630M104 (CUSIP Number) Time Poly Management Ltd. Unit 06, 21/F, Beautiful Group Tower, 77 Connaught Road, Central, Hong Kong Telephone: (852) 3583 3340; Fax: (852) 3585 6021 (Name, Address and Telephone Number of |
|
| April 2, 2010 |
SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No.) VISCORP, INC. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 92832T107 (CUSIP Number) Stewart Shiang Lor 11th Floor, South Tower, Jinjiang Times Garden, 107 Jin Li Road West, Chengdu, Sichuan Province, the People?s Republic of China. Telephone: (852) 3583 3340; Fax: (852) 3585 6021 (Name, Addres |
|
| April 2, 2010 |
SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) TIANYIN PHARMACEUTICAL CO., INC. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 88630M1045 (CUSIP Number) Cmark Holdings Co., Ltd. Unit 06, 21/F, Beautiful Group Tower, 77 Connaught Road, Central, Hong Kong Telephone: (852) 3583 3340; Fax: (852) 3585 6021 (Name, Address and Telephone Number of |
|
| March 31, 2010 |
Louis Taubman (Admitted NY) Email [email protected] March 31, 2010 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Filed September 24, 2009 File No. 001-34189 Dear Mr. Wyman: This letter is provided in response to your letter dated |
|
| March 31, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A |X| ANNUAL REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2009 || TRANSITION REPORT PURSUANT TO SECTION 13 OF 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: TIANYIN PHARMACEUTICAL CO., INC. (formerl |
|
| March 30, 2010 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act March 29, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| March 30, 2010 |
TIANYIN APPOINTS DR. JAMES JIAYUAN TONG AS CHIEF FINANCIAL OFFICER AND CHIEF BUSINESS & DEVELOPMENT OFFICER DR. TONG ALSO JOINS THE BOARD OF DIRECTORS CHENGDU, China, March 29, 2010 /Xinhua-PRNewswire-FirstCall/ - Tianyin Pharmaceutical Co., Inc., (NYSE Alternext: TPI), a manufacturer and supplier of modernized traditional Chinese medicine (“TCM”) based in Chengdu, China, today announced that it h |
|
| March 18, 2010 |
Louis Taubman (Admitted NY) Email [email protected] March 17, 2010 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Mr. Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 File No. 001-34189 Dear Mr. Wyman: I am counsel to Tianyin Pharmaceutical Co., Inc. (“Tianyin”). Tianyin received your |
|
| March 4, 2010 |
SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.1) TIANYIN PHARMACEUTICAL CO., INC. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 88630M1045 (CUSIP Number) Cmark Holdings Co., Ltd. Unit 06, 21/F, Beautiful Group Tower, 77 Connaught Road, Central, Hong Kong Telephone: (852) 3583 3340; Fax: (852) 3585 6021 (Name, Address and Telephone Number of Pe |
|
| February 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Tianyin Pharmaceutical Co., Inc. (Name of issuer) Common Stock, $0.001 par value per share (Title of class of securities) 88630M104 (CUSIP number) December 31, 2009 (Date of event which requires filing of this statement) Check the appropriate box to desi |
|
| February 10, 2010 |
CURRENT REPORT FOR ISSUERS SUBJECT TO THE 1934 ACT REPORTING REQUIREMENTS FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act February 8, 2010 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co. |
|
| February 10, 2010 |
TIANYIN PHARMACEUTICAL CO., INC. ANNOUNCES RECORD SECOND QUARTER 2010 FINANCIAL RESULTS TIANYIN PHARMACEUTICAL CO., INC. ANNOUNCES RECORD SECOND QUARTER 2010 FINANCIAL RESULTS Ø Q2 2010 Revenue Increased 47.9% to $14.9 Million, Net Income Increased 24.8% to $2.6 Million with adjusted EPS of $0.11 on a diluted basis Ø Cash and Equivalents of $19.9 Million on December 31, 2009 Ø First-half 2010 Cash Flow from Operations Increased 24.5% to $4.9 million Ø Tianyin secured SFDA approvals f |
|
| February 10, 2010 |
Tianyin Pharmaceutical Co., Inc. Second Quarter Fiscal 2010 Earnings February 8, 2010 Operator: Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Tianyin Pharmaceutical Second Quarter Fiscal 2010 Earnings conference call. During today?s presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be opened for questions. If yo |
|
| February 8, 2010 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2009 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number Tianyin Pharmaceutical Co |
|
| January 14, 2010 |
Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road SouthChengdu, P. R. China, 610041 January 14, 2010 U.S. Securities and Exchange Commission Division of Corporate Finance Washington, D.C. 20549 Attn: Michael Rosenthal Re: Tianyin Pharmaceutical Co., Inc. Pre-Effective Amendment No. 1 Registration Statement on Form S-3 Filed December 28, 2009 File No. 3 |
|
| December 30, 2009 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION INFORMATION REQUIRED IN PROXY STATEMENT Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [ ] Preliminary Proxy Statement [] Confidential, for Use of the Commissio |
|
| December 28, 2009 |
December 24, 2009 U.S. Securities and Exchange Commission Division of Corporate Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Michael Rosenthall Re: Tianyin Pharmaceutical Co., Inc. Registration Statement on Form S-3 Filed December 8, 2009 File No. 333-163563 Dear Mr. Rosenthall: This letter is provided in response to your letter dated December 22, 2009 regarding the above-referenced re |
|
| December 28, 2009 |
As filed with the Securities and Exchange Commission on December 28, 2009 S-3/A 1 tpis3a163563.htm TIANYIN PHARMACEUTICAL CO., INC. As filed with the Securities and Exchange Commission on December 28, 2009 Registration No. 333-163563 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 /A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tianyin Pharmaceutical Co., Inc. (Exact name of registrant as specified in charter) Delaware (State |
|
| December 8, 2009 |
As filed with the Securities and Exchange Commission on December 8, 2009 As filed with the Securities and Exchange Commission on December 8, 2009 &# 160; Registration No. |
|
| November 17, 2009 |
Tianyin 8-K Exhibit 99.1 Presentation Next Tianyin 8-K Exhibit 99.1 Presentation Next |
|
| November 17, 2009 |
Tianyin Pharmaceutical Co., Inc. (AMEX:TPI) Earnings Call Transcript Friday, November 13, 2009 10:30 AM ET Call Participants Executives Analysts Stewart Lor Angel Liu Director Allen Tang Greg Goldberg Assistant to Chief Executive Officer Matthew Hayden Yale Jen Founder and President Maxim Group LLC James Tong Roth Capital Partners, LLC Page 1 of 13 Presentation Operator Good morning, ladies and ge |
|
| November 17, 2009 |
Tianyin 8-K Exhibit 99.1 Presentation Next Tianyin 8-K Exhibit 99.1 Presentation Next |
|
| November 17, 2009 |
Tianyin 8-K Exhibit 99.1 Presentation Next Tianyin 8-K Exhibit 99.1 Presentation Next |
